Your Sales Playbook and Your Series B Deck Should Be the Same Document

Here is what a typical Series A health tech company looks like at month eighteen. The sales team has a pitch deck, a one-pager, a discovery script, and an objection-handling guide. The founding team is separately building a Series B deck, a financial model, and a growth narrative for investors. Two workstreams. Two story arcs. Two consultants, sometimes.

Nobody has noticed that the story they are telling the buyer and the story they are telling the investor are almost identical, and that keeping them separate is making both worse.

What the investor actually needs to believe

Strip a Series B health tech investment thesis down to its core and it is three things. The problem is real and large. The solution demonstrably works. The commercial motion is repeatable enough to justify the capital to scale it.

Now strip a health system or payer sales conversation down to its core. The problem is real and affects their population. The solution demonstrably works in a comparable setting. The operational lift is manageable and the economics hold.

These are the same argument. The buyer and the investor are both asking: does this work, and does it scale? The evidence they need to be convinced is not meaningfully different. Clinical outcomes data. Defined ICP. Replicable sales motion with named wins. Unit economics that improve with volume. A payer narrative that explains why someone is going to write a check.

The founders who recognize this build one coherent story and stress-test it against both audiences simultaneously. The ones who do not end up with a sales pitch that lacks the precision investors need and an investor deck that lacks the operational specificity buyers require.

Where the separation comes from

The GTM narrative and the fundraising narrative diverge for a structural reason: they are usually owned by different people and run on different timelines. The head of sales or the GTM lead owns the commercial story. The CEO and the CFO own the investor story. They share a Notion page and a quarterly all-hands, but they are not actually building the same thing.

The sales narrative evolves through customer conversations. It gets sharper, more specific, more tuned to what actually moves a buyer. The investor narrative evolves through pitch meetings. It gets broader, more ambitious, more tuned to what a VC wants to see in a market slide.

By the time a company is prepping for a Series B, these two stories have drifted far enough apart that the investor can feel it. The deck says the TAM is $40B. The sales team's best vertical is a single payer segment worth maybe $800M. The deck says the motion is repeatable. The sales team's last three deals each had a different buyer type, a different price, and a different sales cycle. Investors are not stupid. They notice.

What convergence looks like in practice

The companies that get this right are not doing anything exotic. They have built a commercial story rigorous enough that it works in front of an investor, and an investor story grounded enough that it maps to what the sales team is actually doing.

Concretely, the artifacts overlap. The ICP definition the sales team uses for discovery is the same one in the market-sizing slide. The clinical evidence the team uses to close a payer contract is the same evidence in the outcomes section of the pitch. The reimbursement narrative (why someone gets paid, how much, under what conditions) lives in the sales playbook and in the investor deck, because investors need to understand it as well as buyers do. The 18-month growth plan the board reviews each quarter is the same plan the CEO walks investors through in a fundraising meeting, not a cleaned-up version of it.

This sounds obvious. In practice it is rare. Most companies treat the investor deck as a periodic artifact produced for fundraising season. The sales playbook is a living document that gets updated weekly. They are almost never the same document, maintained by the same owner, reviewed against each other for consistency.

The practical implication for a Series A company today

If you are a Series A health tech CEO and you are twelve to eighteen months from a Series B conversation, there is one question worth sitting with: if an investor sat in on your next five sales calls and then read your current pitch deck, would the two stories line up?

If the answer is yes, you are in good shape. The commercial motion is validating the investment thesis in real time, and the investor deck reflects how the business actually works.

If the answer is no, if the deck promises a motion the sales calls do not yet demonstrate, the fix is not to update the deck. It is to build the sales playbook first. Get the commercial story precise enough that it closes deals consistently. Then write the investor narrative around what is actually true. A B round built on a deck that outpaces the operational reality does not hold up in diligence. One built on a sales motion that the team can execute and the investor can verify does.

A few questions worth asking this week

• What is the one-sentence description of the buyer you close most consistently? Does your investor deck use the same description?
• What clinical or outcomes evidence do you use most often in a sales conversation? Is that same evidence the backbone of your investor narrative, or does the investor deck rely on a different proof point?
• If you removed the market-size slide from your deck and replaced it with the three accounts you closed last quarter, would the underlying thesis still hold?
• Who owns the GTM narrative and who owns the investor narrative at your company? When did they last review each other's work?

The founders we see move fastest toward a B round are usually not the ones with the most polished deck. They are the ones whose commercial motion is sharp enough that the investor story writes itself.

— Andrew